Vivek Ramaswamy (Dylan Hollingsworth/Bloomberg via Getty Images)
Following program cuts and amid drug launch, Roivant lines up $1B shelf registration
Roivant Sciences had about $2 billion at the end of June. But the repeat vant-maker wants the option to secure more money for its apparatus …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
